Free Weekly Intelligence Briefing
The biotech intelligence BD teams on both sides rely on
CDE filing translations, deal structure analysis, corporate ownership maps, and BIOSECURE compliance tracking. All drawn from primary Mandarin-language regulatory and corporate sources.
What you get each week
Weekly, 5-7 minute read. From primary Chinese-language sources.
Deal Analysis
We break down the week's biggest licensing deals: financial terms, strategic rationale, and how they compare to benchmarks.
CDE Filing Intelligence
New drug regulatory filings translated and analyzed in English. What is advancing through NMPA and how it compares to Western regulatory pathways.
Corporate Ownership Maps
Who actually owns the Chinese company you're evaluating? We map VIE structures, SOE connections, and subsidiary chains through Chinese corporate registries.
BIOSECURE Compliance Watch
BCC list updates, enforcement timeline tracking, and what it means for your Chinese CDMO/CRO contracts.
Key Takeaways
Every issue closes with concrete observations for your next BD meeting or compliance review.
Built for: VP Business Development · General Counsel · Healthcare VCs · BIOSECURE Compliance · Law Firm Partners
See what you'll receive each week
Preview from our latest briefing
Biotech Intelligence #12: What the GSK-Hengrui Deal Really Says About China Licensing
GSK-Hengrui's roughly $12B multi-asset deal suggests Western pharma is getting more comfortable underwriting Chinese platform depth. Also this week: BIOSECURE timing, CDE signals, and what WuXi exposure really means.
Read the full briefing →The biotech opportunity in numbers
Cross-border Out-Licensing 2025
$137.7B
↑ +140% YoY
Large Pharma Deals
38%
→ of $50M+ deals in H1 2025
Biotechs with CN CDMO
79%
→ have at least one contract
BCC Designation Deadline
Dec 2026
→ OMB BCC list publication
Why this briefing exists
Biotech Intelligence is written by Antony Tan, a computational biologist at Harvard with research experience at the Broad Institute and a publication at NeurIPS 2025. Fluent in English, Mandarin, and Cantonese, Antony works directly from CDE filings, Tianyancha and GSXT corporate registries, and NMPA regulatory documents in their original language.
Every deal analysis, CDE translation, and corporate ownership map is built from primary sources. The same regulatory filings and registry databases used in institutional research, published openly each week.
Independence disclosure: Biotech Intelligence has no financial relationships with any company, institution, or government entity covered in this briefing. All analysis is independent.